MX2021015513A - Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelicula. - Google Patents

Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelicula.

Info

Publication number
MX2021015513A
MX2021015513A MX2021015513A MX2021015513A MX2021015513A MX 2021015513 A MX2021015513 A MX 2021015513A MX 2021015513 A MX2021015513 A MX 2021015513A MX 2021015513 A MX2021015513 A MX 2021015513A MX 2021015513 A MX2021015513 A MX 2021015513A
Authority
MX
Mexico
Prior art keywords
afabicin
bacterial infections
treating bacterial
infections involving
biofilm
Prior art date
Application number
MX2021015513A
Other languages
English (en)
Inventor
Linda Kadi
Justyna Nowakowska
Grègoire VUAGNIAUX
Original Assignee
Debiopharm Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Int Sa filed Critical Debiopharm Int Sa
Publication of MX2021015513A publication Critical patent/MX2021015513A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere al uso de Afabicina en un método de tratamiento de infecciones bacterianas que involucran biopelículas que contienen bacterias Staphylococcus, en donde el método comprende administrar al paciente Afabicina en combinación con al menos un agente adicional seleccionado entre lipopéptidos, glicopéptidos, y lincosamidas, tales como Daptomicina, y/o Vancomicina.
MX2021015513A 2019-06-14 2020-06-12 Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelicula. MX2021015513A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19180281 2019-06-14
PCT/EP2020/066305 WO2020249731A1 (en) 2019-06-14 2020-06-12 Afabicin for use for treating bacterial infections involving biofilm

Publications (1)

Publication Number Publication Date
MX2021015513A true MX2021015513A (es) 2022-04-20

Family

ID=66867028

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015513A MX2021015513A (es) 2019-06-14 2020-06-12 Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelicula.

Country Status (15)

Country Link
US (1) US20230126947A1 (es)
EP (1) EP3982975A1 (es)
JP (1) JP7418475B2 (es)
KR (1) KR20220020963A (es)
CN (1) CN113939306A (es)
AU (1) AU2020293635A1 (es)
BR (1) BR112021025306A8 (es)
CA (1) CA3139942A1 (es)
CL (1) CL2021003317A1 (es)
EA (1) EA202290048A1 (es)
IL (1) IL288861A (es)
MA (1) MA56184A (es)
MX (1) MX2021015513A (es)
SG (1) SG11202113174SA (es)
WO (1) WO2020249731A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003673B2 (en) * 2005-05-31 2011-08-23 Cubist Pharmaceuticals, Inc. Daptomycin for the treatment of biofilm and catheter salvage
NZ702695A (en) 2012-06-19 2015-10-30 Debiopharm Int Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
FR3017294B1 (fr) 2014-02-07 2021-10-01 Atlangram Nanoparticules lipidiques comprenant un antibiotique et leurs utilisations en therapie
US10751351B2 (en) * 2016-02-26 2020-08-25 Debiopharm International S.A. Medicament for treatment of diabetic foot infections

Also Published As

Publication number Publication date
KR20220020963A (ko) 2022-02-21
CL2021003317A1 (es) 2022-09-20
JP2022535598A (ja) 2022-08-09
MA56184A (fr) 2022-04-20
IL288861A (en) 2022-02-01
BR112021025306A8 (pt) 2022-09-20
US20230126947A1 (en) 2023-04-27
EA202290048A1 (ru) 2022-03-10
WO2020249731A1 (en) 2020-12-17
SG11202113174SA (en) 2021-12-30
EP3982975A1 (en) 2022-04-20
BR112021025306A2 (pt) 2022-02-01
AU2020293635A1 (en) 2022-01-27
CN113939306A (zh) 2022-01-14
JP7418475B2 (ja) 2024-01-19
CA3139942A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
MX2017014020A (es) Terapia antimicrobiana.
MX2019007613A (es) Terapia de combinacion con compuestos ?-lactamicos sustituidos con amidina e inhibidores de ?-lactamasa para infecciones con cepas bacterianas resistentes a antibioticos.
MX2021002719A (es) Cannabinoides para el tratamiento de infecciones grampositivas incluidas cepas bacterianas resistentes a antibióticos.
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
TW201613575A (en) Treatment of polybacterial infections
IL235526B2 (en) Prevention, disruption and treatment of biofilm with bacteriophage lysin
MX2013000369A (es) Composiciones para el tratamiento de infecciones de pulmon, formuladas para ser administrables mediante aerolizacion, y que incluyen tobramicina.
MX2020006191A (es) Bacteriocinas terapeuticas.
MX2015016319A (es) Terapia de combinacion que comprende oxazolidinona-quinolonas para uso en el tratamiento de infecciones bacterianas.
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
MX2020004118A (es) Composiciones y metodos para tratar enfermedades de liberibacter y otras enfermedades bacterianas.
ZA202102702B (en) Synergistic disinfectant compositions having enhanced antimicrobial efficacy and stability, and methods of using the same
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX2023004188A (es) Compuestos fosfolipidos y usos de estos.
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
MX2019015007A (es) Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb.
MX2017014080A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX2020012543A (es) Diltiazem para usarse en el tratamiento de infecciones microbianas.
MA39955A (fr) Compositions désinfectantes et antimicrobiennes, en particulier pour le domaine vétérinaire
MX2021015513A (es) Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelicula.
MX2022000433A (es) Proteinas de fusion a toxina para el tratamiento de enfermedades relacionadas con infecciones por cmv.
MX2018001512A (es) Composiciones antimicrobianas que comprenden mupirocina y neomicina.
MX2017012539A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
CR20210029A (es) MÉTODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA